Clinical trials: Neoadjuvant Radiotherapy
HNSCC, Radiotherapy
PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy
In patients with locally advanced head and neck squamous cell carcinoma undergoing standard surgical treatment after neoadjuvant immunochemotherapy, can PD-1 inhibitor therapy be used instead of adjuvant radiotherapy for both…
- Conditions
- HNSCC, Radiotherapy, PD-1
- Trial name
- HNC-SYSU-003 (NCT05980715)
- Testing
- PD-1inhibitor, concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 324 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma
177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study
This phase II trial tests whether 177-Lutetium-PSMA given before stereotactic body radiotherapy (SBRT) works to improve cancer control rate in patients with 1-5 prostate cancer tumors that have come back after prior treatment…
- Conditions
- Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- LUNAR (NCT05496959)
- Testing
- Lutetium Lu-177 PNT2002, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer
Histological Response Rate After Mastectomy and Immediate Breast Reconstruction at the End of Neoadjuvant Chemotherapy and Radiotherapy
At present, it is widely admitted not proposing immediate mammary reconstruction when an adjuvant radiotherapy is indicated because of the significant change of the cosmetic result (profit) and it whatever is the technique of…
- Trial name
- HIST-RIC (NCT02679040)
- Testing
- Immediate mammary reconstruction, Chemotherapy, Radiation therapy
- Where
- 10 sites in France
- Volunteers
- 101 people
- Sponsor
- Institut Paoli-Calmettes
Soft Tissue Sarcoma, Adult Soft Tissue Sarcoma
Multiparametric Quantitative MRI and Response to Neoadjuvant Radiotherapy for Soft-tissue Sarcoma
This trial is a prospective, monocentric, with minimal risks and constraints study, conducted in patients with Soft Tissue Sarcoma (STS) of the limbs and trunk with indication for neoadjuvant radiotherapy (RT).
- Conditions
- Soft Tissue Sarcoma, Adult Soft Tissue Sarcoma, Resectable Soft Tissue Sarcoma
- Trial name
- SarQuantIRM (NCT05684874)
- Testing
- Neoadjuvant RT, Pre-radiotherapy mpMRI, Post-radiotherapy mpMRI
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Centre Leon Berard
Esophageal Cancer, Radiation Pneumonitis
Neoadjuvant Therapy for Esophageal Cancer and Cardiopulmonary Physiology
Although recent global trends indicate reduced postoperative mortality after esophagectomy, major morbidity, in particular pulmonary, remains high, with considerable health and economic costs.
- Conditions
- Esophageal Cancer, Radiation Pneumonitis, Pulmonary Fibrosis, Respiratory Failure
- Trial name
- NCT03462524
- Testing
- Esophagectomy
- Where
- 2 sites in Ireland
- Volunteers
- 384 people
- Sponsor
- St. James's Hospital, Ireland
High Grade Sarcoma
Habitat Escalated Adaptive Therapy (HEAT), With Neoadjuvant Radiation for Soft Tissue Sarcoma
The purpose of the study is to utilize radiomic images to precisely locate areas of tumor that can be treated with dose escalation radiation therapy.
- Trial name
- NCT05301283
- Testing
- Intensity Modulated Radiation Therapy (IMRT), MRI
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Locally Advanced Rectal Adenocarcinoma, Neoadjuvant Chemoradiation
Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC
This is a prospective, multicenter, randomized controlled trial aimed at comparing different radiotherapy fractionation regimens combined with sequential dual immunotherapy versus traditional chemoradiotherapy in neoadjuvant…
- Conditions
- Locally Advanced Rectal Adenocarcinoma, Neoadjuvant Chemoradiation, Neoadjuvant Immunotherapy
- Trial name
- RADICAL (NCT07596290)
- Testing
- Short-course radiotherapy, Long-course radiotherapy, Immunotherapy
- Volunteers
- 342 people
- Sponsor
- Beijing Friendship Hospital
Resectable Soft Tissue Sarcoma, Soft Tissue Sarcoma
Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma
This phase Ib trial studies the side effects of navtemadlin and radiation therapy in treating patients with soft tissue sarcoma.
- Trial name
- NCT03217266
- Testing
- Navtemadlin, Radiation Therapy, Surgical Procedure
- Where
- 53 sites in United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Stomach Adenocarcinoma, Gastro-esophageal Junction Cancer
Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of the multimodal treatment, which includes radiotherapy, chemotherapy and anti-PD-1 immunotherapy. The trial is designed using a pick-the-winner strategy.
- Trial name
- TORCH-G (NCT06728657)
- Testing
- HFRT targeted to the primary lesion and positive lymph nodes, PULSAR targeted to the primary lesion and positive lymph nodes, Anti-PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Fudan University
Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v8
An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer
This early phase I trial investigates how well 64Cu-labeled M5A antibody scan works in assessing tumor activity before and after patients with rectal cancer that has spread to nearby tissue or lymph nodes (locally advanced) who…
- Conditions
- Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8
- Trial name
- NCT05245786
- Testing
- Copper Cu 64 Anti-CEA Monoclonal Antibody M5A, Imaging Technique
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- City of Hope Medical Center
Plasma Cell Leukemia in Remission, Plasma Cell Myeloma
Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma
This phase I/II trial studies the side effects and best dose of melphalan and total marrow irradiation and how well they work with autologous stem cell transplantation in treating patients with high-risk multiple myeloma.
- Trial name
- NCT03100877
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Filgrastim
- Where
- United States
- Sponsor
- City of Hope Medical Center
NSCLC
The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
This randomized phase II trial is to explore the clinical efficacy, safety and feasibility of neoadjuvant immunotherapy plus radiotherapy compared with neoadjuvant immunotherapy plus chemotherapy in operable stage II-IIIA (N+)…
- Trial name
- NCT05798845
- Testing
- SBRT+LDRT, Toripalimab, Chemotherapy drug
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Shanghai Chest Hospital
Nasopharyngeal Carcinoma
Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC
The study is to evaluate whether concurrent nimotuzumab could decrease the severe acute treatment-related toxicities compared with concurrent chemoradiotherapy for locoregionally advanced NPC.
- Trial name
- NCT02012062
- Testing
- TPF neoadjuvant chemotherapy, Concurrent chemotherapy with cisplatin during radiotherapy, Concurrent nimotuzumab during radiotherapy
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Fudan University
Rectal Cancer
Tecemotide (L-BLP25) in Rectal Cancer
The objective of this mechanistic study is to determine the impact of tecemotide (L-BLP25) administration on the mucinous glycoprotein 1 - (MUC1) specific immune response in subjects with newly diagnosed rectal cancer who are…
- Trial name
- SPRINT (NCT01507103)
- Testing
- Tecemotide (L-BLP25), cyclophosphamide (CPA), Chemoradiotherapy
- Where
- Netherlands
- Volunteers
- 124 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Rectal Cancer
Study of Therapeutic Targets Tailored Ch and IMRT as Neoadjuvant Treatment in Rectal Carcinoma Patients
The parameter that best correlates with 5 years disease-free survival (DFS ) in patients (pts) with localized rectal cancer (RC) is the pathological TNM staging (ypTNM) after chemo-radiotherapy (Ch-RT).
- Trial name
- TT (NCT01366118)
- Testing
- Therapeutic target tailored chemotherapy
- Where
- Spain
- Volunteers
- 16 people
- Sponsor
- Grupo Hospital de Madrid
Rectal Cancer
Exosomes in Rectal Cancer
The primary aims of this study is to characterize exosomal biomarker levels in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation therapy.
- Trial name
- NCT03874559
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Kansas Medical Center
Cholangiocarcinoma, Hilar Cholangiocarcinoma
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
This is a phase II, single-arm, prospective clinical trial designed to evaluate the efficacy and safety of neoadjuvant therapy combining stereotactic body radiotherapy (SBRT), GP chemotherapy (gemcitabine and…
- Conditions
- Cholangiocarcinoma, Hilar Cholangiocarcinoma, Bile Duct Cancer
- Trial name
- NCT07030140
- Testing
- Stereotactic Body Radiotherapy (SBRT), Tislelizumab, Gemcitabine
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Jinbo Yue
Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage
A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
This is a phase II study evaluating a new combination therapy for untreated extensive-stage small cell lung cancer. The treatment involves an initial phase with the drug Bemotuzumab plus standard chemotherapy and anlotinib…
- Trial name
- NCT07358676
- Testing
- Bemotuzumab + Anlotinib + Chemotherapy + Radiotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Locally Advanced Rectal Cancer (LARC)
SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer
Colorectal cancer ranks as the third most prevalent malignancy worldwide and the second leading cause of cancer-related mortality.
- Trial name
- NCT06864013
- Testing
- Experimental, Control
- Where
- China
- Volunteers
- 116 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Ulcerative Colitis
A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with moderately to severely active Ulcerative Colitis (UC).
- Trial name
- ARTEMIS-UC (NCT04996797)
- Testing
- Tulisokibart, Companion Diagnostic (CDx) Testing
- Where
- 88 sites in United States, Australia and 10 more
- Volunteers
- 178 people
- Sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)